Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 1.00 |
| ▸ | CPT2 | P23786 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | BHMT | Q93088 | 3/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523390 | 1.00 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EHMGCR | |
| SCHEMBL186164 | 1.00 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EHMGCR | |
| SCHEMBL8037883 | 1.00 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EHMGCR | |
| SCHEMBL1832938 | 1.00 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EHMGCR | |
| SCHEMBL14810357 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1KDM4EADRA1A | |
| SCHEMBL22748728 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1TSHRALDH1A1 | |
| SCHEMBL742996 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1TSHRALDH1A1 | |
| SCHEMBL22748689 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1TSHRALDH1A1 | |
| SCHEMBL2496692 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1KDM4EADRA1A | |
| SCHEMBL6697555 | 0.91 | FFAR1 (0.83) | FFAR1CPT2TDP1KDM4EHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0081930-B1 | LONG-CHAIN ALPHA, OMEGA-DICARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Epis S.A. (CH) | 1986-07-30 | — | — | EP | claimed |
| EP-0081930-A1 | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Epis S.A. (CH) | 1983-06-22 | — | — | EP | claimed |
| EP-1001755-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROME X LTD (IL) | 2011-05-11 | — | — | EP | disclosed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1572189-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1539127-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005002557-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ETHER AND SELECTIVE COX-2 INHIBITOR AND USES THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040171585-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | BAR-TANA JACOB (IL) | 2004-09-02 | — | — | US | disclosed |
| US-20040171688-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | BAR-TANA JACOB (IL) | 2004-09-02 | — | — | US | disclosed |
| WO-2004017952-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20020037876-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM | 2002-03-28 | — | — | US | disclosed |
| US-6303653-B1 | THERAPY OF HEPATOCYTE NUCLEAR FACTOR-4.ALPHA..SUP.1 (HNF-4) MEDIATED DISEASE BY ADMINISTERING CARBOXYLIC ACID OR ITS DERIVATIVE WHICH INHIBITS HNF-4 CONTROLLED TRANSCRIPTION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-10-16 | — | — | US | disclosed |
| EP-1001755-A2 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999000116-A2 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (US) | 1999-01-07 | — | — | WO | disclosed |
| US-4689344-A | ANTICHOLESTEROL AGENTS | EPIS S.A. (CH) | 1987-08-25 | — | — | US | disclosed |
| US-4634795-A | TREATMENT OF OBESITY, HYPERLIPIDEMIA, AND MATURITY-ONSET DIABETES | EPIS S.A. (CH) | 1987-01-06 | — | — | US | disclosed |
| EP-0081930-B1 | LONG-CHAIN ALPHA, OMEGA-DICARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Epis S.A. (CH) | 1986-07-30 | — | — | EP | disclosed |
| EP-0081930-A1 | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Epis S.A. (CH) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | FFAR1 1371/4885CPT2 714/4885TDP1 3613/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | FFAR1 265/4885CPT2 434/4885TDP1 3202/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | FFAR1 449/4885CPT2 1268/4885TDP1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.